Melanoma during Ruxolitinib Treatment for Myelofibrosis

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016; 101: 821–829. DOI: https://doi.org/10.3324/haematol.2016.143644

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016; 30: 1701–1707. DOI: https://doi.org/10.1038/leu.2016.148

Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol 2022; 86: 339–344. DOI: https://doi.org/10.1016/j.jaad.2021.10.004

Gambichler T, Stockfleth E, Susok L. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera. J Eur Acad Dermatol Venereol 2022; 36 Suppl 1: 63–65. DOI: https://doi.org/10.1111/jdv.17406

Blechman AB, Cabell CE, Weinberger CH, Duckworth A, Leitenberger JJ, Zwald FO, et al. Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. J Drugs Dermatol 2017; 16: 508–511.